Skip to main content
. 2021 Aug 21;19:131. doi: 10.1186/s12969-021-00625-y

Table 1.

Patterns of methotrexate (MTX) use at the start of etanercept therapya (MTX Assessment Cohort, n = 1681)

Characteristic Combination therapyb Step-up therapyc ETN proximate switchersd ETN remote switcherse MTX add-onf ETN only
All patients (n = 1681), n (%) 258 (15.3) 892 (53.1) 86 (5.1) 86 (5.1) 144 (8.6) 215 (12.8)
JIAg category, n (%)h
 Oligoarthritis (n = 366) 34 (9.3) 184 (50.3) 34 (9.3) 32 (8.7) 29 (7.9) 53 (14.5)
  Persistent (n = 159) 13 (8.2) 74 (46.5) 11 (6.9) 13 (8.2) 12 (7.5) 36 (22.6)
  Extended (n = 178) 15 (8.4) 99 (55.6) 18 (10.1) 19 (10.7) 15 (8.4) 12 (6.7)
  Unknown (n = 29) 6 (20.7) 11 (37.9) 5 (17.2) 0 2 (6.9) 5 (17.2)
 Polyarthritis (RF-)i (n = 736) 113 (15.4) 437 (59.4) 36 (4.9) 31 (4.2) 57 (7.7) 62 (8.4)
 Polyarthritis (RF+) (n = 208) 49 (23.6) 109 (52.4) 3 (1.4) 7 (3.4) 23 (11.1) 17 (8.2)
 Psoriatic arthritis (n = 134) 29 (21.6) 59 (44.0) 4 (3.0) 5 (3.7) 12 (9.0) 25 (18.7)
 Enthesitis related arthritis (n = 163) 23 (14.1) 65 (39.9) 7 (4.3) 4 (2.5) 13 (8.0) 51 (31.3)
 Systemic arthritis (n = 40) 4 (10.0) 23 (57.5) 1 (2.5) 2 (5.0) 9 (22.5) 1 (2.5)
 Undifferentiated arthritis (n = 34) 6 (17.6) 15 (44.1) 1 (2.9) 5 (14.7) 1 (2.9) 6 (17.6)

a In patients with at least 1 study visit 6 months after starting etanercept; b Combination therapy = methotrexate (MTX) started concurrently with etanercept (ETN); c step-up therapy = MTX started > 1 month prior to ETN and continued > 1 month after ETN initiation; d proximate switchers = MTX started> 1 month prior to ETN and discontinued within 1 month prior to or after ETN; e ETN remote switchers = MTX discontinued > 1 month prior to start of ETN; f MTX add-on = MTX started > 1 month after starting ETN; gJIA juvenile idiopathic arthritis; h Denominator for percentage calculations is the n for that category of JIA; iRF rheumatoid factor